

Profiles - Sanofi Pasteur

26 June 2012 | News



ED: Dr Joselito Sta Ana

Joselito Sta Ana sanofipas

Unmatched experience

Sanofi-Pasteur continued with its tryst to introduce innovative vaccines in India

Sanofi Pasteur India, a part of the Sanofi Group clocked an estimated revenues of **₹ 258.73 crore** for fiscal 2011-12. Globally, Sanofi Pasteur, the vaccines division of Sanofi, provides more than one billion doses of vaccine each year.

In India, Sanofi Pasteur has been a leader in pediatric vaccines with brands such as Pentaxim, Okavax, Typhim Vi, and Imovax and also offers several adult vaccines such as Vaxigrip, Pneumo 23 and Stamaril. The company's activities in India are focused on core product franchises namely influenza (seasonal and pandemic influenza), travel and endemic range (rabies, typhoid and yellow fever) and PPMHP (Polio, Pertussis, Meningitis, Haemophilus Influenza and Pneumonia). Today, the company plays an active role in the immunization programs of India.

In terms of main highlights during the year, Sanofi Pasteur announced that it has entered into a marketing and distribution agreement with Emcure Pharmaceuticals in India for its anti-rabies vaccine, Verorab. The product will be imported and supplied by Sanofi Pasteur India and marketed and distributed by Emcure via its subsidiary, Zuventus Healthcare. Under this agreement, Sanofi Pasteur and Emcure will work together to

raise awareness regarding rabies vaccination at the general practitioner and physician level. Zuventus Healthcare will now promote Verorab pan-India to over 60,000 physicians and general practitioners. It also got the government's nod for import of tetravalent dengue vaccines.

Dr Joselito Sta Ana, executive director, Sanofi Pasteur India, said "Sanofi Pasteur remains committed to its fight against rabies. In India, more than 15 million people are bitten by animals, mostly dogs every year and are at risk of developing rabies if no appropriate post exposure prophylaxis is quickly administered. We are excited about this agreement with Emcure, which will reinforce the presence of Verorab all over India." Since its launch in 1987, more than 25 million doses of Verorab, a purified Vero cell rabies vaccine, have been distributed in the country.

| Key Achievements | Performance highlights | Key strategy initiatives | Future plans |
|--|--|---|--|
| <ul style="list-style-type: none"> • Sanofi Pasteur has entered into a marketing and distribution agreement with Emcure for its anti-rabies vaccine, Verorab. • In India, Sanofi Pasteur is the leader in pediatric vaccines and adult vaccines. • Key role in immunizing 10 million people in India. | <ul style="list-style-type: none"> • It focused actively on influenza franchise (seasonal and Pandemic Influenza), travel & endemic range (rabies, typhoid and yellow fever) and PPMH (polio, pertussis, meningitis, haemophilus influenza and pneumo). | <ul style="list-style-type: none"> • To raise awareness regarding the rabies vaccination through Zuventus. | <ul style="list-style-type: none"> • To play an active role in the immunization programs of India, reaching population present in metros and non metro cities alike. • Joining with the strong force of Shanta Biotechnics to look at ensuring reach of affordable vaccines to even the lower strata of society. |